Topics

Imara Submits Confidential Draft Registration Statement for Proposed Initial Public Offering

07:00 EDT 13 Sep 2019 | Businesswire
Imara Inc.

Imara Inc. today announced that it has previously confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (“Securities Act”). This announcement is being issued in accordance with Rule 135 under the Securities Act.

Imara Media Contact:
Krystle Gibbs
Ten Bridge Communications
508-479-6358
krystle@tenbridgecommunications.com

Imara Company / Investor Contact:
Michael Gray
857-320-4636
mgray@imaratx.com

NEXT ARTICLE

More From BioPortfolio on "Imara Submits Confidential Draft Registration Statement for Proposed Initial Public Offering"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...